IBIO Archives - BioTuesdays

Developments

AI and precision biologics innovators, iBio and AstralBio, team to build novel best-in-class obesity treatments

iBio (NYSEA:IBIO) entered into a collaboration agreement with AstralBio to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions. Yesterday, iBio announced a concurrent...

March 27, 2024

Developments

iBio sells preclinical PD-1 agonist antibody program to Otsuka

iBio (NYSEA:IBIO) has sold assets related to its early-stage programmed cell death protein 1 (PD-1 ) agonist program to Otsuka Pharmaceutical. Under the terms of the accord, iBio received an upfront payment of $1.0...

February 27, 2024

Feature

iBio fast-tracking discovery for hard-to-drug targets with precision antibody therapeutics powered by AI and machine learning

iBio (NYSEA:IBO) is developing next-generation biopharmaceuticals leveraging computational biology and 3D-modeling of epitopes enabling the discovery of new antibody treatments for hard-to-target cancers and other...

February 6, 2024

Developments

iBio adds ShieldTx to tech stack, enhances immune-oncology pipeline

iBio (NYSEA:IBIO) launched ShieldTx, a patent-pending antibody masking technology designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue. The addition of...

November 3, 2023

Developments

iBio in pending deal to sell CDMO facility; extends Woodforest credit agreement

iBio (NYSEA:IBIO) announced a sixth amendment to its credit agreement with Woodforest National bank to allow sufficient time for the company to complete the pending sale of its cGMP biologics manufacturing facility. The...

September 22, 2023

Developments

iBio posts positive in vivo proof of concept in 3 immuno-oncology programs

iBio (NYSEA:IBIO) reported positive preclinical in vivo data for three immuno-oncology candidates – an anti-EGFRvIII, CCR8 and a bispecific TROP-2 x CD3 – advancing the three programs to clinical candidate...

August 14, 2023

Executive Moves

iBio names Dr. Martin Brenner and Felipe Duran as permanent CEO and CFO, respectively

iBio (NYSEA:IBIO) appointed Martin Brenner, DVM, Ph.D., as CEO and Felipe Duran as CFO, effective immediately. Dr. Brenner will also continue to serve as iBio’s CSO, a role he has held since December 2020. The...

June 27, 2023

Developments

iBio in pact with NIH to develop Lassa fever vaccine

iBio (NYSEA:IBIO) entered into a research collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), an arm of the National Institutes of Health (NIH), to investigate the potential of iBio’s...

June 12, 2023

Developments

iBio expands tech stack with EngageTx; adds TROP-2 bispecific to pipeline

iBio (NYSEA:IBIO) expanded its AI-powered technology stack with the launch of EngageTx, a proprietary T-cell engager antibody panel designed for developing bispecific antibodies for immuno-oncology applications. Through...

June 6, 2023

Developments

GEN highlights iBio pivot to precision antibody immunotherapies

Genetic Engineering & Biotechnology News (GEN), in a feature article, outlines iBio’s (NYSE American:IBIO) transition from a contract development and manufacturing organization and cGMP biologics manufacturer to a...

May 30, 2023

Tag - IBIO

AI and precision biologics innovators, iBio and AstralBio, team to build novel best-in-class obesity treatments

iBio sells preclinical PD-1 agonist antibody program to Otsuka

iBio fast-tracking discovery for hard-to-drug targets with precision antibody therapeutics powered by AI and machine learning

iBio adds ShieldTx to tech stack, enhances immune-oncology pipeline

iBio in pending deal to sell CDMO facility; extends Woodforest credit agreement

iBio posts positive in vivo proof of concept in 3 immuno-oncology programs

iBio names Dr. Martin Brenner and Felipe Duran as permanent CEO and CFO, respectively

iBio in pact with NIH to develop Lassa fever vaccine

iBio expands tech stack with EngageTx; adds TROP-2 bispecific to pipeline

GEN highlights iBio pivot to precision antibody immunotherapies

General

More